BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results